Literature DB >> 2848929

Interferon inhibits herpes simplex virus-specific translation: a reinvestigation.

B Altinkilic1, G Brandner.   

Abstract

Reports on the arrest of herpes simplex virus type 1 (HSV-1) replication by interferon (IFN) are inconsistent. By the use of immunofluorescence and immunoblot assays with monoclonal and polyclonal antibodies, effective arrest of viral translation by human IFN-alpha in human fibroblasts was detected for the HSV-1 strains KOS and McIntyre. In HeLa cells which are less sensitive to IFN inhibition and in 444 cells, a HeLa-fibroblast hybrid cell line, the inhibition was less pronounced. These results confirm earlier observations that IFN or polyinosinic.polycytidylic acid block the replication of HSV-1 in human, monkey and mouse cells no later than the immediate early phase of infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848929     DOI: 10.1099/0022-1317-69-12-3107

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.

Authors:  Kasey M Eidson; William E Hobbs; Brian J Manning; Paul Carlson; Neal A DeLuca
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Characterization of a potent refractory state and persistence of herpes simplex virus 1 in cell culture.

Authors:  Cristina Barreca; Peter O'Hare
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation.

Authors:  Karen E Johnson; David M Knipe
Journal:  Virology       Date:  2009-10-31       Impact factor: 3.616

5.  Herpes simplex virus ICP0 mutants are hypersensitive to interferon.

Authors:  K L Mossman; H A Saffran; J R Smiley
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Nucleoside metabolism in herpes simplex virus-infected cells following treatment with interferon and acyclovir, a possible mechanism of synergistic antiviral activity.

Authors:  W J O'Brien; E C Coe; J L Taylor
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Activation of interferon response factor-3 in human cells infected with herpes simplex virus type 1 or human cytomegalovirus.

Authors:  C M Preston; A N Harman; M J Nicholl
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of alpha interferon and acyclovir.

Authors:  J L Taylor; P Tom; J Guy; R M Selvarajan; W J O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  IFI16 restricts HSV-1 replication by accumulating on the hsv-1 genome, repressing HSV-1 gene expression, and directly or indirectly modulating histone modifications.

Authors:  Karen E Johnson; Virginie Bottero; Stephanie Flaherty; Sujoy Dutta; Vivek Vikram Singh; Bala Chandran
Journal:  PLoS Pathog       Date:  2014-11-06       Impact factor: 6.823

10.  African Swine Fever Virus EP364R and C129R Target Cyclic GMP-AMP To Inhibit the cGAS-STING Signaling Pathway.

Authors:  Niranjan Dodantenna; Lakmal Ranathunga; W A Gayan Chathuranga; Asela Weerawardhana; Ji-Won Cha; Ashan Subasinghe; Nuwan Gamage; D K Haluwana; YongKwan Kim; WeonHwa Jheong; Haryoung Poo; Jong-Soo Lee
Journal:  J Virol       Date:  2022-07-21       Impact factor: 6.549

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.